Frank Peacock
ORAGENICSAbout Frank Peacock
William “Frank” Peacock, MD, was appointed Chief Clinical Officer (CCO) of Oragenics on May 22, 2024, to oversee the company’s planned Phase II clinical trial for ONP‑002 in concussion treatment . He serves as Vice Chair for Emergency Medicine Research at Baylor College of Medicine and is a former Professor at the Cleveland Clinic Lerner College of Medicine; he has led concussion biomarker trials and edited “Biomarkers of Traumatic Brain Injury” . Age, education details, and executive-specific performance metrics (TSR, revenue/EBITDA during tenure) are not disclosed in Oragenics’ filings; the appointment was filed under Item 8.01 (press release) rather than Item 5.02 (compensatory arrangements) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Baylor College of Medicine | Vice Chair for Emergency Medicine Research | Not disclosed | Leads ED research; expertise in biomarkers and acute care translates to clinical trial execution at OGEN |
| Cleveland Clinic Lerner College of Medicine | Professor (past) | Not disclosed | Academic leadership and clinical research pedigree underpin trial design/oversight |
| Concussion biomarker trial (company not named) | Principal Investigator | Not disclosed | Work on acute blood markers to identify concussion and predict severity supports ONP‑002 development strategy |
| Editor, “Biomarkers of Traumatic Brain Injury” | Editor | Not disclosed | Domain authority enhances credibility with investigators and regulators |
External Roles
| Organization | Role | Committee/Focus | Years |
|---|---|---|---|
| Baylor College of Medicine | Vice Chair, Emergency Medicine Research | Emergency medicine research and trials | Not disclosed |
| Cleveland Clinic Lerner College of Medicine | Professor (past) | Academic medicine | Not disclosed |
Fixed Compensation
- Base salary, target bonus, and actual bonus for the CCO are not disclosed; the appointment was announced via press release (Item 8.01) without compensatory details typically found in Item 5.02 .
- The 2025 proxy (DEF 14A) details named executive officer pay but does not include the CCO; thus, no CCO-specific fixed pay data is available .
Performance Compensation
- No disclosures of performance metrics, incentive weightings, or payout outcomes for the CCO (e.g., revenue, EBITDA, TSR, ESG) are available; the appointment filing did not include compensatory arrangements .
- Company-wide equity plan allows performance awards, clawbacks, and prohibits repricing, but CCO-specific grants/targets are not disclosed .
Equity Ownership & Alignment
- Total beneficial ownership: The CCO is not listed among beneficial owners or named officers in the DEF 14A table as of March 21, 2025; equity holdings and vested/unvested breakdowns are not disclosed .
- Pledging/hedging: No disclosures identify pledging or hedging by the CCO; no CCO-specific ownership guidelines or compliance status are provided .
Employment Terms
- Employment agreement: Not disclosed for the CCO in SEC filings; the May 22, 2024 8‑K was limited to a press release (Item 8.01) with no contract terms .
- Severance and change‑of‑control: No CCO-specific severance multiples or triggers disclosed; while the company’s 2021 Equity Incentive Plan describes change-in-control mechanics and award handling, it does not specify the CCO’s individual terms .
Investment Implications
- Clinical execution leverage: Peacock’s biomarker expertise and emergency medicine leadership should strengthen ONP‑002 Phase II trial design, site engagement, and early endpoint selection, a key execution lever for value creation in concussion therapeutics .
- Data-readiness and regulatory credibility: His track record editing a domain-defining text and leading ED biomarker trials can improve credibility with investigators and regulators, potentially de‑risking early clinical milestones .
- Alignment/retention opacity: Absence of disclosed employment economics (salary, bonus, equity grants, severance, CoC, vesting) limits assessment of pay‑for‑performance alignment, insider selling pressure, and retention risk; monitoring future 8‑K 5.02 events and proxies is warranted .
- Governance and incentive framework: Company-wide plan features (no option repricing, clawbacks, director equity caps) suggest prudent governance; however, without CCO-specific grant terms, investor visibility into incentive alignment remains limited .
Monitoring actions: Watch for subsequent 8‑K Item 5.02 filings or DEF 14A updates that specify CCO compensation, equity grants, and employment terms; track any insider filings for ownership changes or pledging.